Page last updated: 2024-09-04

allotrap and Colitis Gravis

allotrap has been researched along with Colitis Gravis in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buelow, R; Coppola, D; Flanigan, A; Murthy, S	1
Holtmann, MM	1
Hoffmann, JC	1
Fong, T; Hawkey, C; Lazarov, M; Tesi, RJ; Travis, S; Warren, B; Yap, LM	1

Reviews

1 review(s) available for allotrap and Colitis Gravis

Article	Year
RDP-58 (SangStat Medical). IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:12 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Peptides; Structure-Activity Relationship	2003

Trials

1 trial(s) available for allotrap and Colitis Gravis

Article	Year
RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflammatory bowel diseases, 2005, Volume: 11, Issue:8 Topics: Administration, Oral; Adult; Colitis, Ulcerative; Colonoscopy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intestinal Mucosa; Male; Middle Aged; Peptides; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome	2005

Article

Year

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

Inflammatory bowel diseases, 2005, Volume: 11, Issue:8

Topics: Administration, Oral; Adult; Colitis, Ulcerative; Colonoscopy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Intestinal Mucosa; Male; Middle Aged; Peptides; Probability; Reference Values; Risk Assessment; Severity of Illness Index; Treatment Outcome

2005

Other Studies

2 other study(ies) available for allotrap and Colitis Gravis

Article	Year
RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2002, Volume: 51, Issue:11 Topics: Animals; Biological Availability; Chronic Disease; Colitis, Ulcerative; Colon; Dextran Sulfate; Dogs; Feces; Female; Macaca mulatta; Mice; Occult Blood; Peptides; Tissue Distribution; Tumor Necrosis Factor-alpha	2002
[Inflammatory bowel disease: anti-TNF strategies and beyond]. Deutsche medizinische Wochenschrift (1946), 2004, Sep-03, Volume: 129 Suppl 2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Infliximab; Intercellular Adhesion Molecule-1; Natalizumab; Peptides; Receptors, Interleukin-6; Signal Transduction; Tumor Necrosis Factor-alpha	2004

Article

Year

RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2002, Volume: 51, Issue:11

Topics: Animals; Biological Availability; Chronic Disease; Colitis, Ulcerative; Colon; Dextran Sulfate; Dogs; Feces; Female; Macaca mulatta; Mice; Occult Blood; Peptides; Tissue Distribution; Tumor Necrosis Factor-alpha

2002

[Inflammatory bowel disease: anti-TNF strategies and beyond].

Deutsche medizinische Wochenschrift (1946), 2004, Sep-03, Volume: 129 Suppl 2

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Infliximab; Intercellular Adhesion Molecule-1; Natalizumab; Peptides; Receptors, Interleukin-6; Signal Transduction; Tumor Necrosis Factor-alpha

2004